Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art

References

• Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353–358. [PMID: 8228129].
   PubMed Web of Science ®Google Scholar
• Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–148. [PMID: 11786970].
   PubMed Web of Science ®Google Scholar
• Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005;54:718–725. [PMID: 15831923]
   Google Scholar
• Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2018 Dec 12:pii: S0016–5085(18)35402–7. [PMID: 30552895]. DOI:10.1053/j.gastro.2018.12.005
   PubMedGoogle Scholar
• Shizuma T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: a literature review. World J Hepatol. 2018;10(2):254–266. [PMID: 29527261].
   PubMed Web of Science ®Google Scholar
• Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56:S1–S12. [PMID: 22300459].
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Branco JC, Barosa R, et al. Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2016;28(10):1216–1222. [PMID: 27391170].
   PubMed Web of Science ®Google Scholar
• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. [PMID: 16298014].
   PubMed Web of Science ®Google Scholar
• Marciano S, Dirchwolf M, Bermudez CS, et al. Spontaneous bacteremia and spontaneous bacterial peritonitis share similar prognosis in patients with cirrhosis: a cohort study. Hepatol Int. 2018;12(2):181–190. [PMID: 29224053].
   PubMed Web of Science ®Google Scholar
• Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122(4):923–930. [PMID: 11910344].
   PubMed Web of Science ®Google Scholar
• Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495–1501. [PMID: 7982650].
   PubMed Web of Science ®Google Scholar
• Tandon P, Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2011;9(3):260–265. [PMID: 21145427].
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406–460. [PMID: 29653741].
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–1324. [PMID: 24530646].
   PubMed Web of Science ®Google Scholar
• Bauer TM, Steinbrückner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–2967. [PMID: 11693333].
   PubMed Web of Science ®Google Scholar
• Lachar J, Bajaj JS. Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis. Semin Liver Dis. 2016;36(4):327–330. [PMID: 27997972].
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–321. [PMID: 26962397].
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Agiasotelli D, Vasilieva LE, et al. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30(5):486–497. [PMID: 28845103].
   PubMed Web of Science ®Google Scholar
• Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2005;17(1):27–31. [PMID: 26380651].
   PubMed Web of Science ®Google Scholar
• Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol. 2011;55(3):574–581. [PMID: 21236309].
   PubMed Web of Science ®Google Scholar
• Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol. 2009;51(3):426–429. [PMID: 19615779].
   PubMed Web of Science ®Google Scholar
• Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2008;47(2):729–736. [PMID: 18167066].
   PubMed Web of Science ®Google Scholar
• Muñoz L, José Borrero M, Ubeda M, et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology. 2012;56(5):1861–1869. [PMID: 22611024].
   PubMed Web of Science ®Google Scholar
• Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int. 2018;38(Suppl 1):126–133. [PMID: 29427501].
   PubMedGoogle Scholar
• Piano S, Salinas F, Morando F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial. J Hepatol. 2015;62:S241. [PMID: 26084406].
   PubMed Web of Science ®Google Scholar
• Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci. 2017;62(2):345–356. [PMID: 28514703].
   PubMed Web of Science ®Google Scholar
• Marciano S, Dirchwolf M, Diaz JM, et al. Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. Eur J Gastroenterol Hepatol. 2018 Dec 14. In print. PMID: 30557229. DOI:10.1097/MEG.0000000000001331
   PubMedGoogle Scholar
• Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int. 2013;33(7):975–981. [PMID: 23522099].
   PubMed Web of Science ®Google Scholar
• Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol. 2015;7(7):916–921. [PMID: 25954474].
   PubMed Web of Science ®Google Scholar
• Piroth L, Pechinot A, Di Martino V, et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis. 2014;14:287. [PMID: 24884471].
   PubMed Web of Science ®Google Scholar
• Marciano S, Díaz JM, Dirchwolf M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat Med. 2019 Jan 14;11:13–22. [PMID: 30666172].
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979–985. [PMID: 20621200].
   PubMed Web of Science ®Google Scholar
• de Mattos AA, Costabeber AM, Lionço LC, et al. Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management? World J Gastroenterol. 2014;20(39):14079. [PMID: 25339797].
   PubMed Web of Science ®Google Scholar
• Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018 Dec;155(6):1816–1827. [PMID: 30144431].
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Gentile I, et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: a systematic review. World J Gastroenterol. 2017;23(25):4654–4660. [PMID: 28740354].
   PubMed Web of Science ®Google Scholar
• Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multidrug resistance in hepatology. J Hepatol. 2016;65(5):1043–1054. [PMID: 27544545].
   PubMed Web of Science ®Google Scholar
• Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol. 2016;64(3):717–735. [PMID: 26519602].
   PubMed Web of Science ®Google Scholar
• Hwang SY, Yu SJ, Lee JH, et al. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis. 2014;33(2):259–264. [PMID: 23996048].
   PubMed Web of Science ®Google Scholar
• Fiore M, Leone S. Spontaneous fungal peritonitis: epidemiology, current evidence and future prospective. World J Gastroenterol. 2016;22(34):7742–7747. [PMID: 27678356].
   PubMed Web of Science ®Google Scholar
• Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27(5):1207–1212. [PMID: 9581672].
   PubMed Web of Science ®Google Scholar
• Bernard B, Grangé JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655–1661. [PMID: 10347104].
   PubMed Web of Science ®Google Scholar
• de Franchis R, Faculty BVI, Baveno VI. Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. [PMID: 26047908].
   PubMed Web of Science ®Google Scholar
• Bernard B, Cadranel JF, Valla D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995;108(6):1828–1834. [PMID: 7768389].
   PubMed Web of Science ®Google Scholar
• Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39(3):746–753. [PMID: 14999693].
   PubMed Web of Science ®Google Scholar
• Fernández J, Tandon P, Mensa J, et al. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology. 2016;63(6):2019–2031. [PMID: 26528864].
   PubMed Web of Science ®Google Scholar
• Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91(6):1343–1346. [PMID: 3770358].
   PubMed Web of Science ®Google Scholar
• Schwabl P, Bucsics T, Soucek K, et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver Int. 2015;35(9):2121–2128. [PMID: 25644943].
   PubMed Web of Science ®Google Scholar
• Andreu M, Solá R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis. Gastroenterology. 1993;104:1133–1138. [PMID: 8462803].
   PubMed Web of Science ®Google Scholar
• Hoefs JC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med. 1983;102:260–273. [PMID: 6864073].
   PubMed Web of Science ®Google Scholar
• Terg R, Casciato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–1060. [PMID: 25481567].
   PubMed Web of Science ®Google Scholar
• Bruns T, Lutz P, Stallmach A, et al. Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts. J Hepatol. 2015 Aug;63(2):527–528. [PMID: 26015370].
   PubMed Web of Science ®Google Scholar
• Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol. 2011;55:1010–1016. [PMID: 21356257].
   PubMed Web of Science ®Google Scholar
• Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010;51:1327–1333. [PMID: 20087966].
   PubMed Web of Science ®Google Scholar
• Casper M, Mengel M, Fuhrmann C, et al. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. Trials. 2015 Mar;8(16):83. [PMID: 25887140].
   PubMedGoogle Scholar
• Lutz P, Berger C, Langhans B, et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis. 2014;46:1047–1050. [PMID: 25086996].
   PubMedGoogle Scholar
• Mandorfer M, Schwabl P, Paternostro R, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018 Apr;47(7):980–988. [PMID: 29377193].
   PubMed Web of Science ®Google Scholar
• Simbrunner B, Röthenbacher A, Haslacher H, et al. Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterol J. 2019 Jun;7(5):651–661. [PMID: 31210943].
   PubMed Web of Science ®Google Scholar
• Menshawy A, Mattar O, Barssoum K, et al. Safety and efficacy of rifaximin in prophylaxis of spontaneous bacterial peritonitis: a systematic review and meta-analysis. Curr Drug Targets. 2019;20(4):380–387. [PMID: 30246636].
   PubMed Web of Science ®Google Scholar
• Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007 Sep;133(3):818–824. [PMID: 17854593].
   PubMed Web of Science ®Google Scholar
• Grangé JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol. 1998 Sep;29(3):430–436. [PMID: 9764990].
   PubMed Web of Science ®Google Scholar
• Novella M, Solà R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology. 1997 Mar;25(3):532–536. [PMID: 9049193].
   PubMed Web of Science ®Google Scholar
• Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol. 2008 May;48(5):774–779. [PMID: 18316137].
   PubMed Web of Science ®Google Scholar
• Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995 Oct;22(4 Pt 1):1171–1174. [PMID: 7557868].
   PubMed Web of Science ®Google Scholar
• Yim HJ, Suh SJ, Jung YK, et al. Daily norfloxacin vs. Weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol. 2018 Aug;113(8):1167–1176. [PMID: 29946179].
   PubMed Web of Science ®Google Scholar
• Assem M, Elsabaawy M, Abdelrashed M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016 Mar;10(2):377–385. [PMID: 26660707].
   PubMed Web of Science ®Google Scholar
• Lontos S, Shelton E, Angus PW, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis. 2014 May;15(5):260–267. [PMID: 24612987].
   PubMed Web of Science ®Google Scholar
• Alvarez RF, Mattos AA, Corrêa EB, et al. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol. 2005 Oct-Dec;42(4):256–262. [PMID: 16444382].
   PubMedGoogle Scholar
• Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International ascites club. J Hepatol. 2000;32(1):142–153. [PMID: 10673079].
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Papagiouvanni I, Cela M, et al. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int. 2019. in press. Epub ahead of print. [PMID: 30920712]. DOI:10.1111/liv.14109
   PubMedGoogle Scholar
• Kimer N, Pedersen JS, Tavenier J, et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol. 2018 Jan;33(1):307–314.
   PubMed Web of Science ®Google Scholar
• Kimer N, Pedersen JS, Busk TM, et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology. 2017 Feb;65(2):592–603.
   PubMed Web of Science ®Google Scholar
• Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716–724. [PMID: 2210673].
   PubMed Web of Science ®Google Scholar
• Titó L, Rimola A, Ginès P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8(1):27–31. [PMID: 3257456].
   PubMed Web of Science ®Google Scholar
• Huang CH, Lin CY, Sheen IS, et al. Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. Liver Int. 2011;31(2):184–191. [PMID: 21143367].
   PubMed Web of Science ®Google Scholar
• Goel A, Rahim U, Nguyen LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017;46(11–12):1029–1036. [PMID: 28994123].
   PubMed Web of Science ®Google Scholar
• Dever JB, Sheikh MY. Editorial: spontaneous bacterial peritonitisbacteriology, diagnosis, treatment, risk factors and prevention. Authors’ reply. Aliment Pharmacol Ther. 2015;41(12):1298–1298. [PMID: 25968149].
   PubMed Web of Science ®Google Scholar
• Min YW, Lim KS, Min BH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695–704. [PMID: 25078671].
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753e1–759e2. [PMID: 25130937].
   Web of Science ®Google Scholar
• Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60:1851–1860. [PMID: 25048618].
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017 2;Feb(2):94–102. [PMID: 28403995].
   Google Scholar
• Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018 Jun 16;391(10138):2417–2429. [PMID: 29861076].
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015 Feb;35(2):362–369. [PMID: 24836902].
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911–921. [PMID: 23262249].
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016 Mar;64(3):574–582. [PMID: 26519600].
   PubMed Web of Science ®Google Scholar
• Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–799. [PMID: 21354230].
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Bota S, Schwabl P, et al. Nonselective b blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–1690.e1. [PMID: 24631577].
   PubMed Web of Science ®Google Scholar
• Bossen L, Krag A, Vilstrup H, et al. Non-selective β-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three RCTs with 1198 patients. Hepatology. 2015 Nov 24. DOI:10.1002/hep.28352. [Epub ahead of print] [PMID: 26599983].
   Web of Science ®Google Scholar
• Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2017. in press. [PMID: 28994122]. DOI:10.1111/apt.14366
   PubMed Web of Science ®Google Scholar
• Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016 Aug;14(8):1096–1104. [PMID: 26829026].
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Roy S, Livadas S, et al. Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites. Dig Dis Sci. 2018 Jul;63(7):1737–1746. PMID: 30697445.
   PubMed Web of Science ®Google Scholar
• Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of betablockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967–969. [PMID: 22234982].
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014 Mar;60(3):643–653. [PMID: 24076364].
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. When should the β-blocker window in cirrhosis close? Gastroenterology. 2014 Jun;146(7):1597–1599. [PMID: 24768679].
   PubMed Web of Science ®Google Scholar
• Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017 Apr;66(4):849–859.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017 Jan;49(1):3–10.
   PubMedGoogle Scholar